BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions
Data support development of next-generation APJ agonists for obesity and key comorbidities
EMERYVILLE, Calif., June 21, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA) ('BioAge', 'the Company'), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that it will present new preclinical data supporting apelin receptor (APJ) agonism for the treatment of diabetic obesity and heart failure with preserved ejection fraction (HFpEF). The data will be presented at the American Diabetes Association's 85th Scientific Sessions, held June 20–23, 2025, in Chicago, Illinois.
'Our preclinical data demonstrated that APJ activation can confer multiple benefits in models of diabetic obesity and heart failure, and enhance the effects of incretin therapy,' said Kristen Fortney, PhD, CEO and co‑founder of BioAge. 'We are advancing next‑generation APJ agonists to translate this promising biology into new therapies for obesity and its major comorbidities.'
APJ is the receptor for apelin, an exercise-induced signaling molecule known as an exerkine. Apelin has been shown in preclinical studies to have the potential to recapitulate many of the downstream benefits of exercise. BioAge's discovery platform identified apelin signaling as a therapeutic target based on analysis of human aging cohorts, which revealed that higher levels of circulating apelin are predictive of improved physical function and increased longevity. BioAge has shown that in preclinical obesity models, APJ agonism can approximately double the weight loss induced by GLP-1 receptor agonists while restoring body composition and muscle function, suggesting that APJ agonists could serve as pharmacological exercise mimetics to enhance incretin therapy.
BioAge is advancing multiple APJ agonist approaches, including both oral small-molecule and long-acting injectable formulations, with an IND filing targeted for 2026 [link].
In their two presentations, BioAge CMO and EVP Research Paul Rubin, MD, and scientist Shijun Yan, PhD, MBA, will present data that demonstrated that in preclinical models of diabetic obesity and HFpEF, APJ agonist treatment had potential as monotherapy that could be enhanced in combination with incretin therapies.
—Dr. Rubin's oral presentation will show that in mouse models of diabetic obesity, APJ agonist monotherapy reduced HbA1c to levels comparable to lean controls and improved glucose tolerance by 25%. When combined with an incretin, APJ agonism further improved glycemic control compared to the incretin alone. Currently, fewer than half of patients with type 2 diabetes achieve optimal glycemic control on current incretin therapies.
— Dr. Yan's poster will show that in a mouse model of obesity-associated heart failure, APJ agonist monotherapy reduced cardiac hypertrophy and suppressed markers of cardiac injury. Combination of APJ agonism with an incretin provided enhanced cardioprotective benefits and greater weight loss compared to either treatment alone. Over half of heart failure patients have preserved ejection fraction, and approximately two-thirds of these patients have obesity. Current therapeutic options for obesity-associated HFpEF remain limited.
Oral presentation: Saturday Jun 21, 2025 5:00 PM - 5:15 PM CDTTitle: An Oral Apelin Receptor Agonist Enhances Glycemic Control in Preclinical Models of Diabetic Obesity Both as Monotherapy and in Combination with TirzepatideSession: Early Phase, Post Hoc, and Subgroup Analyses from Clinical Trials Testing Incretin-Based Therapies—Take 1; W181 A-CPresenter: Paul Rubin, MD, Chief Medical Officer and EVP-Research
Poster presentation: Sunday Jun 22, 2025 12:30 PM - 1:30 PM CDTTitle: The Apelin Receptor Agonist Azelaprag Shows Cardioprotective Effects as Monotherapy and Enhanced Benefits with Semaglutide in a Diet-Induced Obesity Model of Heart Failure with Preserved Ejection FractionSession: Poster Hall F1, Board No. 866Presenter: Shijun Yan, PhD, MBA, Senior Scientist, In Vivo Biology
The visual materials for the presentations will be made available on the BioAge investor website https://ir.bioagelabs.com concurrent with the beginning of their respective sessions.
About BioAge Labs, Inc.
BioAge is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The Company's lead product candidate, BGE-102, is a potent, orally available, brain-penetrant small-molecule NLRP3 inhibitor being developed for obesity. BGE-102 has demonstrated significant weight loss in preclinical models both as monotherapy and in combination with GLP-1 receptor agonists. IND submission and initiation of a Phase 1 SAD/MAD trial are planned for mid-2025, with initial SAD data anticipated by end of year. The Company is also developing long-acting injectable and oral small molecule APJ agonists for obesity. BioAge's additional preclinical programs, which leverage insights from the Company's proprietary discovery platform built on human longevity data, address key pathways involved in metabolic aging.
Forward-looking statements
This press release contains 'forward-looking statements' within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding our plans to develop and commercialize our product candidates, including BGE-102 and our APJ program, the timing and results of our planned clinical trials, risks associated with clinical trials, including our ability to adequately manage clinical activities, the timing of our IND filing for BGE-102 or our APJ program, our ability to obtain and maintain regulatory approvals, the clinical utility of our product candidates or their ultimate ability to treat human disease, the expected timeline for completing proteomic analysis, anticipated analytical results and the potential for identifying novel therapeutic targets, and general economic, industry and market conditions. These forward-looking statements may be accompanied by such words as 'aim,' 'anticipate,' 'believe,' 'could,' 'estimate,' 'expect,' 'forecast,' 'goal,' 'intend,' 'may,' 'might,' 'plan,' 'potential,' 'possible,' 'will,' 'would,' and other words and terms of similar meaning. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including: our ability to develop, obtain regulatory approval for and commercialize our product candidates; the timing and results of preclinical studies and clinical trials; the risk that positive results in a preclinical study or clinical trial may not be replicated in subsequent trials or success in early stage clinical trials may not be predictive of results in later stage clinical trials; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; the occurrence of adverse safety events; failure to protect and enforce our intellectual property, and other proprietary rights; failure to successfully execute or realize the anticipated benefits of our strategic and growth initiatives; risks relating to technology failures or breaches; our dependence on collaborators and other third parties for the development of product candidates and other aspects of our business, which are outside of our full control; risks associated with current and potential delays, work stoppages, or supply chain disruptions, including due to the imposition of tariffs and other trade barriers; risks associated with current and potential future healthcare reforms; risks relating to attracting and retaining key personnel; changes in or failure to comply with legal and regulatory requirements, including shifting priorities within the U.S. Food and Drug Administration; risks relating to access to capital and credit markets; and the other risks and uncertainties that are detailed under the heading 'Risk Factors' included in BioAge's Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission (SEC) on May 6, 2025, and BioAge's other filings with the SEC filed from time to time. BioAge undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.ContactsPR: Chris Patil, media@bioagelabs.com IR: Dov Goldstein, ir@bioagelabs.com Partnering: partnering@bioagelabs.com Web: https://bioagelabs.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
30 minutes ago
- Yahoo
Investors in OptimizeRx (NASDAQ:OPRX) have unfortunately lost 55% over the last three years
It is doubtless a positive to see that the OptimizeRx Corporation (NASDAQ:OPRX) share price has gained some 73% in the last three months. But that is small recompense for the exasperating returns over three years. Indeed, the share price is down a tragic 55% in the last three years. Some might say the recent bounce is to be expected after such a bad drop. While many would remain nervous, there could be further gains if the business can put its best foot forward. It's worthwhile assessing if the company's economics have been moving in lockstep with these underwhelming shareholder returns, or if there is some disparity between the two. So let's do just that. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. Because OptimizeRx made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size. Over three years, OptimizeRx grew revenue at 16% per year. That's a fairly respectable growth rate. So some shareholders would be frustrated with the compound loss of 16% per year. The market must have had really high expectations to be disappointed with this progress. So this is one stock that might be worth investigating further, or even adding to your watchlist. The image below shows how earnings and revenue have tracked over time (if you click on the image you can see greater detail). We consider it positive that insiders have made significant purchases in the last year. Having said that, most people consider earnings and revenue growth trends to be a more meaningful guide to the business. So we recommend checking out this free report showing consensus forecasts It's good to see that OptimizeRx has rewarded shareholders with a total shareholder return of 34% in the last twelve months. Notably the five-year annualised TSR loss of 1.3% per year compares very unfavourably with the recent share price performance. The long term loss makes us cautious, but the short term TSR gain certainly hints at a brighter future. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Take risks, for example - OptimizeRx has 1 warning sign we think you should be aware of. If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: most of them are flying under the radar). Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
30 minutes ago
- Yahoo
MIT engineers thrilled after developing game-changing 3D printing technique: 'This is an exciting path'
MIT researchers have developed a clever 3D printing trick that could save materials and simplify cleanup. What sets it apart is the supports used during printing dissolve easily and can even be reused, meaning less work for you and less waste for the planet. Right now, resin 3D printing relies on scaffolding to hold detailed pieces in place. Not only is peeling off supports tedious, but they often go straight into the bin, to. The MIT method fixes that by using a special resin that reacts differently to two types of light. UV light hardens the printed part; visible light hardens the supports, which dissolve later in a safe solvent such as baby oil. Bonus: that solution can be filtered and turned into fresh resin again. Lead researcher Nicholas Diaco says the trick lies in juggling the chemistry: adding a third "bridge" molecule so UV curing gives strength where it matters while keeping the support layers weak enough to wash away. The special resin tackles two big headaches of resin printing, which are the hassle of support removal and the waste that those supports create. Industry studies estimate supports can make up 10-20% of a final print, and most go to waste. The Massachusetts Institute of Technology showed the material can be collected, reused, and repurposed, saving money and helping reduce plastic pollution. A broader concern is that traditional 3D printing creates specialty plastic scraps and emits tiny particles into the air. MIT's approach helps by cutting scrap at its source and reducing how much needs to be handled afterward. And since supports can be dissolved, the cleanup is safer for users and the planet. This isn't just a university toy. It could change how dentists, engineers, and makers build dental pieces, lifelike models, and tiny moving parts without so much filing, clipping, and resin waste. Researchers are also using 3D printing to improve wastewater treatment by designing custom microbial reactors that clean water and generate energy at the same time. Additive manufacturing is finding new roles in sustainability far beyond plastics. The MIT team says it's working on improving print detail and resin flexibility. "We'll continue studying the limits of this process, and we want to develop additional resins with this wavelength-selective behavior and mechanical properties necessary for durable products," professor of mechanical engineering John Hart said. "Along with automated part handling and closed-loop reuse of the dissolved resin, this is an exciting path to resource-efficient and cost-effective polymer 3D printing at scale." The scientists hope this could reach labs and light manufacturing in the next few years. That means fewer landfill-bound supports, quicker cleanup, and smoother designs to be used in real-world applications. Would you trust a home made of recycled plastic? Absolutely Depends on the cost Depends what it looks like No way Click your choice to see results and speak your mind. Join our free newsletter for weekly updates on the latest innovations improving our lives and shaping our future, and don't miss this cool list of easy ways to help yourself while helping the planet.
Fox News
35 minutes ago
- Fox News
The heat has a surprising effect on the brain — here's what doctors want you to know
Summer heat has swept the U.S., with warnings issued across the East Coast and Midwest. In addition to putting stress on the body, hot weather can also take a toll on the brain and mental health. Dr. Jace Reed, director of emergency psychiatry at Cedars-Sinai Hospital in Los Angeles, emphasized in an interview with Fox News Digital that the brain is a major organ that can be greatly affected by heat. Extreme heat can cause mental health changes like increased irritability and anxiety, along with decreased memory, attention and reaction time. This can affect daily interactions socially and professionally, the expert cautioned. "You may be slower at completing your task or remembering what someone just told you," he told Fox News Digital. "Those can be initial early signs that the heat is affecting your brain and your mental abilities." Symptoms like extreme confusion could mark the beginning of a heat stroke, which could require hospitalization, the psychiatrist warned. In a separate interview with Fox News Digital, Thea Gallagher, a doctor of psychology and director of wellness programs at NYU Langone Health, noted that when the body overheats, it struggles to regulate internal balance. This can lead to disrupted sleep, fatigue and poor concentration, as well as impaired cognitive function, slow reaction times and struggles with decision-making. The heat can also increase oxidative stress and inflammation in the brain, Gallagher added, which can potentially damage neurons, worsen existing neurological conditions and raise stroke risk. "Heat exposure may trigger an inflammatory response in the brain," she said. "In cases like heatstroke, inflammation is believed to contribute to symptoms such as confusion and delirium." Excessive heat can also weaken the protective blood-brain barrier, according to the expert, which makes the brain more vulnerable to toxins and pathogens. Higher temperatures are also associated with disturbances in mood and violent behavior, especially during prolonged heatwaves. Psychiatric emergency visits for anxiety, depression and substance use also rise significantly on the hottest days, Gallagher confirmed. Below are some of the main mental symptoms that can worsen in hot weather, experts cautioned. People who suffer from mental health conditions such as mood disorders, schizophrenia, anxiety or even dementia are more vulnerable in hot weather. Some psychiatric medications could make it difficult for the body to regulate temperature or stay hydrated, Gallagher noted, while heat can "intensify" symptoms like agitation or paranoia. "People with cognitive impairments may not recognize the signs of overheating," she added. "Some SSRIs (selective serotonin reuptake inhibitors) can suppress sweat production, which is the body's primary cooling mechanism. This raises the risk of overheating, dehydration and even heat stroke." "Paradoxically, SSRIs can also cause excessive sweating in some individuals — a side effect known as 'SSRI sweats,'" she went on. "While this might seem like it would help with cooling, it can actually lead to dehydration if fluid intake doesn't keep up." The experts recommended the following practices to protect brain health in extreme heat. For more Health articles, visit "Days are also longer and there are more activities, which can be exhausting," Gallagher noted. "Therefore, it is good to prioritize sleep and rest … and [find] ways to slow down when you can."
